
A cohort study revealed that obstructive uropathy significantly increases the risk of cancer and associated mortality. Among 37,275 patients diagnosed with obstructive uropathy between 1996 and 2022, the 3-month cancer risk was 9.6%, with a standardized incidence ratio (SIR) of 34.2. Notably, the 3-month SIR was 82.7 for urological cancer, 88.8 for gynecological cancer, and 13.9 for colorectal cancer. The risk of urological cancers decreased significantly after one year. Additionally, the 5-year all-cause mortality for cancer patients with a prior obstructive uropathy diagnosis was 64.1%, compared to 53.2% for those without. These findings suggest that obstructive uropathy may be a clinical marker for undiagnosed cancer and predict worse outcomes in cancer patients.
Like
Save
Share